Ozemback
Quiz

Approved, recommended, or neither?

Ten compounds. For each one, say whether the FDA has approved it, whether an advisory committee merely recommended it in July 2026, or whether nothing happened to it at all. Most people score badly, and almost everyone errs the same way: they assume the July vote made things legal.

Answers verified against the committee record · 12 November 2026
Question 1 of 10Score 0

 

 

The source behind every answer

Every answer on this page comes from one table: FDA approval, the committee vote with its tally, and the 503A position, each with a date.

Open the status tracker →

Every question and its answer, in plain text

Listed here so the answers are readable without playing, and quotable with their source.

BPC-157: approved, recommended, or neither?
Recommended, not law. No published randomised controlled trial in humans for any indication. FDA approval: Not approved. July 2026 committee: In favour, 8 to 6 with 1 abstention.
KPV: approved, recommended, or neither?
Recommended, not law. A tripeptide fragment of alpha-MSH. FDA found no study of KPV given to humans, by any route. FDA approval: Not approved. July 2026 committee: In favour, 8 to 6 with 1 abstention, against FDA staff advice.
TB-500: approved, recommended, or neither?
Recommended, not law. A fragment of thymosin beta-4, not the same molecule. FDA found no published study of TB-500 given to humans. FDA approval: Not approved. July 2026 committee: In favour, 8 to 6 with 1 abstention, against FDA staff advice.
MOTS-c: approved, recommended, or neither?
Recommended, not law. A mitochondrial-derived peptide sold for weight loss. FDA found no study of it in humans by any route and no animal toxicity study. Two abstentions, the most of the six that passed. FDA approval: Not approved. July 2026 committee: In favour, 7 to 5 with 2 abstentions, against FDA staff advice.
Epitalon: approved, recommended, or neither?
Recommended, not law. Carries the largest longevity claims and the thinnest human evidence base. FDA found no clinical safety data and no study in people with insomnia. FDA approval: Not approved. July 2026 committee: In favour, 7 to 4 with 1 abstention, against FDA staff advice.
Semax: approved, recommended, or neither?
Recommended, not law. Registered as a medicine in Russia. That is not an FDA approval. FDA found no human pharmacokinetic study by any route. FDA approval: Not approved. July 2026 committee: In favour, 8 to 5 with 1 abstention, against FDA staff advice.
Emideltide: approved, recommended, or neither?
Recommended against. The only one of the seven the committee voted down. FDA approval: Not approved. July 2026 committee: Against, 6 to 7.
Sermorelin: approved, recommended, or neither?
Neither. Discontinued by the manufacturer in 2008. Compounded today under a different pathway. FDA approval: Formerly approved as Geref. No approved product today.. July 2026 committee: Not among the seven reviewed.
CJC-1295: approved, recommended, or neither?
Neither. FDA cites reported serious adverse events, including increased heart rate and a systemic vasodilatory reaction (FDA safety-risk page, current as of 22 April 2026). FDA approval: Not approved. July 2026 committee: Not among the seven reviewed.
Ipamorelin: approved, recommended, or neither?
Neither. FDA cites a published report of serious adverse events, including death, after intravenous use (FDA safety-risk page, current as of 22 April 2026). FDA approval: Not approved. July 2026 committee: Not among the seven reviewed.
What this quiz is, and what it is not

Every question here is about regulatory status: what a regulator has approved, what a committee recommended, what the paperwork says today. None of it is medical advice, none of it is a recommendation to take or avoid anything, and a score tells you how well you know the rules, not what is right for you.

Legal status and clinical suitability are different questions, and neither one answers the other. A compound can be legal and wrong for you. It can be unapproved and still the subject of serious research. This page does not help you decide, and it is not trying to.

Ozemback is an independent publication, not a provider. It does not recommend doses, protocols or treatments and takes no part in any clinical decision. Talk to a licensed clinician before starting, stopping or changing anything. See the full terms and editorial disclaimer.

Ozemback is independent journalism. Nothing on this site is medical advice. Nothing replaces a licensed clinician. Read the disclaimer